Hate Checking Your Portfolio? Try These 2 Stocks

If your portfolio is stressing you out, these two stocks could take a load off your mind.

I have good news for those of you who hate checking your portfolio every time the stock market makes an abrupt change: There are plenty of companies in the healthcare sector poised to grow in tandem with rising average life spans across the developed world.

Two of my favorites, Johnson & Johnson (NYSE:JNJ) and Medtronic (NYSE:MDT), enjoy strong competitive advantages that have allowed them to steadily increase their dividend payments for decades. Let’s look at some reasons you can expect them to continue doing so throughout your lifetime.

Johnson & Johnson: no more tears

If uncertainty makes your eyes sweat, then adding shares of the world’s largest healthcare conglomerate to your portfolio might help. In a sense, you can’t find a safer company in America. Johnson & Johnson is one of just two U.S. companies with a pristine “AAA” debt rating. The other, Microsoft, recently earned a negative outlook from Moody’s after offering LinkedIn $26.2 billion for a buyout.

If an unsullied debt rating doesn’t soothe your frayed nerves, then consider its earnings growth and dividend history. Despite some hairy global economic downturns, J&J’s adjusted earnings have risen for 32 consecutive years, and its dividend hasn’t stalled since JFK was in office.

Past performance doesn’t guarantee future success, but J&J’s diversified revenue stream reads like a recipe for continued growth. The consumer-goods segment contains iconic brands, some of which date to the 19th century.

In case you’re new to biopharma, Tylenol isn’t the only J&J drug that brings in over $1 billion in annual sales. Its prescription pharmaceutical segment has grown in recent years, and it accounted for about 47% of J&J’s $18.5 billion in total second-quarter revenue. One of several promising drugs in its lineup, Invokana, is a first-in-class tablet for Type 2 diabetics that allows excess blood sugar to exit through the patient’s urinary tract. Approved in 2013, Invokana saw second-quarter sales rise 20.4% over the prior-year period, putting the drug at an annual run rate of about $1.5 billion.

Idf Diabetes Atlas


It appears Invokana has plenty of room to grow. Last year an estimated $673 billion was spent treating diabetes, and that number is likely to continue growing. The disease affects a staggering 415 million people worldwide, and roughly half are undiagnosed. I haven’t asked all of them how they feel about injecting insulin, but I think we can safely assume most would prefer swallowing Invokana tablets.

Medtronic: why bigger is better

As the world’s largest medical-device manufacturer, Medtronic enjoys economies of scale that allow it to sell devices at price points that smaller competitors struggle to match, and that’s not its only advantage. Last year’s $49.9 billion acquisition of Covidien gave Medtronic an industry-leading array of med-tech offerings that make it a one-stop shop for hospitals.

Another advantage is the sticky relationships its salesforce has built up over the years. Trained sales reps are often a busy doctor’s most efficient source of information about new devices. Combine this with the time and expense associated with training staff, and switching to a competitor’s devices becomes a daunting proposition.

The Covidien acquisition also gave Medtronic an opportunity to redomicile in Ireland just before that door slammed shut. Switching from one of the world’s highest corporate tax rates to the lowest will help the company meet its fiscal 2017 guidance. Management expects adjusted earnings per share to grow between 12% and 16% in fiscal 2017 and expects double-digit earnings growth over the long term.

Getty Images Doctor Sales Representative


Medtronic also loves returning those profits to shareholders. This June it raised its quarterly dividend by 13% to $0.43 per share, marking 39 consecutive years of increased payments at an 18% annual growth rate.

The company is committed to returning at least half of its free cash flow to shareholders, which forces it to avoid M&A for the sake of looking busy and remain focused on increasing profitability. If this combination of relatively predictable growth and discipline doesn’t help you relax about checking your portfolio, then you should probably see a doctor.

Alert: Will Apple’s newest product stun investors?
Why did Apple quietly lease an enormous, 5000-acre abandoned military base, what on earth are they spending $10 billion on, and who knows exactly what’s behind ‘Project Titan’?

We may have just found the incredible answer – and more.

You see, this research also reveals 3 stocks to buy before Apple unveils what could be the next must have product. Click here now to read the full report now.

*The author(s) may have a position in any stocks mentioned. The Motley Fool owns and recommends shares of Apple. 

Cory Renauer owns shares of Johnson and Johnson and Medtronic. You can follow Cory on Twitter @TMFang4apples or connect with him on LinkedIn for more healthcare industry insight. 

The Motley Fool owns shares of and recommends Johnson and Johnson. The Motley Fool owns shares of LinkedIn, Medtronic, and Microsoft. The Motley Fool recommends Moody’s. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


You May Also Like

Pride Week Festival Begins With Tribute to Pulse Nightclub Survivor

Miami Beach Pride’s week-long festivities will commence with a special tribute to the LGBTQ+ community honoring the victims of the tragic shooting at Pulse Nightclub in Orlando. A ceremonial “flip

Surfside luxury condo sees notable sales

Arte at Surfside is making waves. There’s, of course, the news that Ivanka Trump and Jared Kushner are renting at the 16-resident luxury condominium. And there’s the December penthouse sale

Up in the Air: A Discussion

In a dynamic region where residents are typically on the move, everyone is wondering about the health of the airline industry and the safety of airports and airplanes. Everyone is

South Florida Yachting Legend Passes

Robert “Bob” Roscioli, an icon in the South Florida marine industry, has passed away. Many recognize the name Roscioli from the widely-successful and world-renowned Roscioli Yachting Center, a full service

Other Posts

Four key steps

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column width=”2/3″][vc_column_text] What a crazy time we are all experiencing. Right now, getting back to basics is most important. It is not and

Pandemic adds to worries about hurricane season

An above-normal 2020 Atlantic hurricane season is expected, according to forecasters with NOAA’s Climate Prediction Center, a division of the National Weather Service. The outlook predicts a 60% chance of

The difference between leading and managing

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column width=”2/3″][vc_column_text] Leadership and management are often misunderstood as one in the same. They are not. Certainly, a good leader should be able

Flattening the housing curve in a pandemic

By Josh Migdal In the classic film Groundhog Day (and yes, it is a classic), Bill Murray’s character wakes up over and over again in Punxsutawney, Pennsylvania, reliving the same

Drew Limsky

Drew Limsky



Drew Limsky joined Lifestyle Media Group in August 2020 as Editor-in-Chief of South Florida Business & Wealth. His first issue of SFBW, October 2020, heralded a reimagined structure, with new content categories and a slew of fresh visual themes. “As sort of a cross between Forbes and Robb Report, with a dash of GQ and Vogue,” Limsky says, “SFBW reflects South Florida’s increasingly sophisticated and dynamic business and cultural landscape.”

Limsky, an avid traveler, swimmer and film buff who holds a law degree and Ph.D. from New York University, likes to say, “I’m a doctor, but I can’t operate—except on your brand.” He wrote his dissertation on the nonfiction work of Joan Didion. Prior to that, Limsky received his B.A. in English, summa cum laude, from Emory University and earned his M.A. in literature at American University in connection with a Masters Scholar Award fellowship.

Limsky came to SFBW at the apex of a storied career in journalism and publishing that includes six previous lead editorial roles, including for some of the world’s best-known brands. He served as global editor-in-chief of Lexus magazine, founding editor-in-chief of custom lifestyle magazines for Cadillac and Holland America Line, and was the founding editor-in-chief of Modern Luxury Interiors South Florida. He also was the executive editor for B2B magazines for Acura and Honda Financial Services, and he served as travel editor for Conde Nast. Magazines under Limsky’s editorship have garnered more than 75 industry awards.

He has also written for many of the country’s top newspapers and magazines, including The New York Times, Washington Post, Los Angeles Times, Miami Herald, Boston Globe, USA Today, Worth, Robb Report, Afar, Time Out New York, National Geographic Traveler, Men’s Journal, Ritz-Carlton, Elite Traveler, Florida Design, Metropolis and Architectural Digest Mexico. His other clients have included Four Seasons, Acqualina Resort & Residences, Yahoo!, American Airlines, Wynn, Douglas Elliman and Corcoran. As an adjunct assistant professor, Limsky has taught journalism, film and creative writing at the City University of New York, Pace University, American University and other colleges.